ALK-Abelló A/S
ALK-B
Peringkat dalam Saham
#2431
ALK-Abelló A/S is a global leader in allergy solutions, with operations... ALK-Abelló A/S is a global leader in allergy solutions, with operations spanning Europe, North America, and other international regions. The company offers a comprehensive portfolio of treatments for allergic rhinitis and allergic asthma, featuring key products such as GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDACURE, and ITULAZAX. ALK-Abelló specializes in allergy immunotherapy, providing options like injections, sublingual drops, and tablets to address a wide range of sensitivities, including those to grass, ragweed, house dust mites, Japanese cedar, various tree pollens, and certain foods. Furthermore, the company engages with consumers through a digital healthcare ecosystem, a platform designed to connect with allergy sufferers early in their journey, offering tools, e-commerce solutions, and guidance to support and streamline access to immunotherapy. ALK-Abelló also provides essential diagnostic allergy services, including skin prick and blood tests, alongside emergency treatments such as intramuscular adrenaline injections for severe, life-threatening allergic reactions like anaphylaxis. The company was established in 1923 and is based in Hørsholm, Denmark.
Harga Saham
$36.23
Terakhir disinkronkan: 2026-10-16
Kapitalisasi Pasar
$8.04B
Perubahan (1 hari)
-1.72%
Perubahan (1 tahun)
12.00%
Negara
DK
Perdagangan ALK-Abelló A/S (ALK-B)
Kategori
Healthcare
Kapitalisasi pasar dari ALK-Abelló A/S(ALK-B)
Kapitalisasi Pasar: $8.04B
Per October 2026, ALK-Abelló A/S memiliki kapitalisasi pasar sebesar $8.04B. Ini menjadikan ALK-Abelló A/S sebagai perusahaan 2431st paling bernilai di dunia menurut data kami. Kapitalisasi pasar adalah nilai total saham beredar dari perusahaan publik dan biasanya digunakan untuk mengukur seberapa besar nilai sebuah perusahaan.
Riwayat kapitalisasi pasar ALK-Abelló A/S dari 2009 hingga 2026
ALK-B dibandingkan dengan 5 teratas stocks paling populer
